Medicago Inc.
Description Medicago Inc., a clinical-stage biotechnology company, develops novel vaccines and therapeutic proteins to treat various infectious diseases worldwide. The company develops its vaccines based on its proprietary technologies comprising the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidates include H5N1 pandemic influenza VLP vaccine, which has completed a Phase II human clinical trial; and seasonal influenza and H1N1 vaccines. The companys products under development also comprise non-influenza VLP and rabies vaccine candidates. It has a strategic alliance with Mitsubishi Tanabe Pharma Corporation to develop a Rotavirus vaccine candidate; and research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Medicago Inc. was incorporated in 1997 and is headquartered in Quebec, Canada. To view the detailed information, you need to SUBSCRIBE with us. |
 |